Tco conjugates and methods for delivery of therapeutic agents
US-2017095580-A1 · Apr 6, 2017 · US
Chemical structures for localized delivery of therapeutic agents
US10130711B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10130711-B2 |
| Application number | US-201414899041-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2014 |
| Priority date | Jun 19, 2013 |
| Publication date | Nov 20, 2018 |
| Grant date | Nov 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising: an implantable biocompatible solid support selected from the group consisting of polysaccharide hydrogels, alginate, cellulose, hyaluronic acid, chitosan, chitin, chondroitin sulfate, heparin, a polymer matrix, a metal, a ceramic and a plastic; at least one binding agent linked to the biocompatible solid support, wherein the at least one binding agent is capable of a bioorthogonal reaction with a corresponding binding agent and the bioorthogonal reaction is between a trans-cyclooctene and a tetrazine; and a linker covalently linking each binding agent to the implantable biocompatible solid support. 2. The composition of claim 1 , wherein the implantable biocompatible solid support comprises alginate. 3. The composition of claim 1 , wherein the composition has the structure of the formula: 4. The composition of claim 1 , wherein the implantable biocompatible solid support is selected from the group consisting of alginate, chitin, hyaluronic acid and chitosan. 5. The composition of claim 4 , wherein the implantable biocompatible solid support is hyaluronic acid. 6. The composition of claim 1 , wherein the composition is formulated in a sterile injectable preparation. 7. The composition of claim 1 , wherein the at least one binding agent comprises trans-cyclooctene or tetrazine. 8. The composition of claim 1 , wherein the at least one binding agent is trans-cyclooctene or tetrazine. 9. The composition of claim 1 , wherein the implantable biocompatible solid support comprises the polymer matrix.
Assignees
Inventors
Classifications
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antibacterial agents · CPC title
Drugs for skeletal disorders · CPC title
for bone diseases, e.g. rachitism, Paget's disease · CPC title
Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10130711B2 cover?
- The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the t…
- Who is the assignee on this patent?
- Univ California, Alchemcial Res Holdings Llc, Alchemical Res Holdings Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/36. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).